SRRA News and Press, Sierra Oncology Inc. From 06/21/21

Sierra Oncology Announces Completion of Enrollment for MOMENTUM Phase 3 Trial Canada NewsWire —Topline data anticipated in Q1 2022 with NDA filing to follow in H2 2022— SAN MATEO, Calif. , June 21, 2021 /CNW/ - Sierra Oncology, Inc. (NASDAQ:...

Sierra Oncology Hosting KOL Panel Event to Discuss Momelotinib Data Presented at EHA 2021 Canada NewsWire --Chief Medical Officer Dr. Barbara Klencke , to be joined by leading myelofibrosis experts Drs. Aaron Gerds , Stephen Oh and Srdan Verstovsek-- ...

Momelotinib Oral Presentation at European Hematology Association Demonstrates Association Between Transfusion Independence and Improved Overall Survival Canada NewsWire —Additional poster presentation highlights improved transfusion independence of momelotinib i...

Sierra Oncology Welcomes Two New Independent Directors to its Board Canada NewsWire —Georgia Erbez and Christy Oliger bring additional strategy, finance and commercial experience as Sierra prepares for commercialization of momelotinib— SAN MAT...

Sierra Oncology Announces Presentation at Jefferies Healthcare Conference PR Newswire SAN MATEO, Calif. , May 25, 2021 /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare for...

Sierra Oncology Announces Abstracts Accepted for American Society of Clinical Oncology Annual Meeting PR Newswire —New momelotinib analysis examining the association between transfusion independence and overall survival to be presented— SAN MA...

Sierra Oncology Announces Oral Presentation at European Hematology Association Annual Meeting Canada NewsWire –  Oral presentation for new momelotinib analysis examines association between transfusion independence and overall survival – ...

Sierra Oncology Reports First Quarter 2021 Results PR Newswire – Pivotal MOMENTUM Phase 3 Trial Anticipated to Complete Enrollment in June 2021 – – Topline Data Now Expected in Q1 2022 – SAN MATEO, Calif. , May 7, 2021 ...

The following slide deck was published by Sierra Oncology, Inc. in conjunction with this event. For further details see: Sierra Oncology (SRRA) Investor Presentation - Slideshow

Sierra Oncology (SRRA): Q4 GAAP EPS of -$1.63 misses by $0.11.Revenue of $0.2MPress Release For further details see: Sierra Oncology EPS misses by $0.11